CLINICAL & PIPELINE·Phase 3 Completion
Summit Therapeutics Bolsters Ivonescimab's FDA Case with Updated Phase 3 Survival Data
Summit Therapeutics has strategically released updated overall survival data from its Phase 3 HARMONi trial for ivonescimab, a PD-1xVEGF bispecific antibody. This move aims to bolster the drug's profile ahead of a critical FDA decision, signaling a proactive regulatory approach. Decision-makers should monitor this development closely for its implications on future oncology treatment landscapes and potential supply chain shifts in the United States.
90-Day Activity